Conflicts of Interest PJM chairs a data safety committee for Bristol-Meyers Squibb and has in the past received lecture fees from Novartis, Astellas, Roche and Genzyme.
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
Article first published online: 29 SEP 2011
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation
Volume 24, Issue 12, pages 1216–1230, December 2011
How to Cite
Pengel, L. H. M., Liu, L. Q. and Morris, P. J. (2011), Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transplant International, 24: 1216–1230. doi: 10.1111/j.1432-2277.2011.01357.x
- Issue published online: 3 NOV 2011
- Article first published online: 29 SEP 2011
- Received: 9 June 2011 Revision requested: 6 July 2011 Accepted: 30 August 2011
Figure S1 Forest plot indicating the odds ratio of the occurrence of lymphoceles in kidney transplant recipients on mTOR inhibitors plus antimetabolites.
Figure S2 Forest plot indicating the odds ratio of the occurrence of wound complications in heart transplant recipients on mTOR inhibitors plus CNIs.
Table S1. mTOR inhibitors plus belatacept in kidney transplantation (n=1).
Table S2. mTor inhibitors plus CNIs for heart transplantation (n=4).
Table S3. mTOR inhibitors in liver transplantation (n=1).
Table S4. mTor inhibitors in simultaneous pancreas kidney transplantation (n=1).
Table S5. RCTs that investigated mTOR inhibitors combined with steroids versus no steroids in kidney transplantation (n=2).
Table S6. Description of wound-related events and whether lymphoceles were reported for each RCT included in the systematic review.
Table S7. Subgroup analysis for RCTs of good methodological quality, i.e., adequate allocation concealment or a total Jadad score of at least three for RCTs in kidney transplantation. The number of trials refers to the number of RCTs that were of good methodological quality according to each of the quality criteria including the total number of patients included in the analysis.
|TRI_1357_sm_TableS1-S7.doc||214K||Supporting info item|
|TRI_1357_sm_figure1.jpg||1390K||Supporting info item|
|TRI_1357_sm_figure2.jpg||1021K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.